Cat. No.: HY-10244

MK-0608

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

MK-0608 is a potent and orally bioavailable inhibitor of HCV replication in vitro with an EC₅₀ of 0.3 μM (EC₉₀=1.3 μM) in the subgenomic-replicon assay.

For research use only. We do not sell to patients.

Purity: 99.81%
CAS No.: 443642-29-3
Formula: C₁₂H₁₆N₄O₄
Molecular Weight:280.28

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

MK-0608 Chemical Structure

CAS No.: 443642-29-3

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vivo
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

MK-0608 is a potent and orally bioavailable inhibitor of HCV replication in vitro with an EC₅₀ of 0.3 μM (EC₉₀=1.3 μM) in the subgenomic-replicon assay^[1].

IC₅₀ & Target

EC50: 0.3 μM (HCV replication)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
H1-HeLa	EC₅₀	5.1 μM Compound: MK-0608b	Antirhinovirus activity in HRVM infected in H1-HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by Cell-Titer Glo viability assay Antirhinovirus activity in HRVM infected in H1-HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by Cell-Titer Glo viability assay	[PMID: 25897704]
HeLa	CC₅₀	>50 μM Compound: MK-0608b	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 25897704]
Huh-7	CC₅₀	>100 μM Compound: 2	Cytotoxicity against Huh7 cells after 24 hrs by MTS assay Cytotoxicity against Huh7 cells after 24 hrs by MTS assay	[PMID: 17521911]
Huh-7	CC₅₀	>100 μM Compound: 2'CMe-7-deaza-adenosine	Cytotoxicity against human HuH7 cells by MTT assay Cytotoxicity against human HuH7 cells by MTT assay	[PMID: 24944743]
Huh-7	CC₅₀	>100 μM Compound: 1	Cytotoxicity against human HuH7 cells Cytotoxicity against human HuH7 cells	[PMID: 23453067]
Huh-7	CC₅₀	>89 μM Compound: 2'-C-Me 7-deaza A	Cytotoxicity against human HuH7 cells after 24 hrs by MTS assay Cytotoxicity against human HuH7 cells after 24 hrs by MTS assay	[PMID: 22578461]
Huh-7	CC₅₀	50 μM Compound: DMA	Cytotoxicity against human Huh-7 cells Cytotoxicity against human Huh-7 cells	[PMID: 38377828]
Huh-7	EC₅₀	0.08 μM Compound: 2'-C-Me 7-deaza A	Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as cytoprotection after 24 hrs Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as cytoprotection after 24 hrs	[PMID: 22578461]
Huh-7	EC₅₀	0.11 μM Compound: 2	Antiviral activity against HCV genotype 1b in Huh7 cells assessed as inhibition of viral RNA replication after 72 hrs by ribonuclease protection assay Antiviral activity against HCV genotype 1b in Huh7 cells assessed as inhibition of viral RNA replication after 72 hrs by ribonuclease protection assay	[PMID: 17521911]
Huh-7	EC₅₀	0.2 μM Compound: 2'CMe-7-deaza-adenosine	Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH7 cells assessed as inhibition of subgenomic replicon RNA replication after 72 hrs by luciferase reporter assay Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH7 cells assessed as inhibition of subgenomic replicon RNA replication after 72 hrs by luciferase reporter assay	[PMID: 24944743]
Huh-7	EC₅₀	0.3 μM Compound: 2	Antiviral activity against HCV genotype 1b in Huh7 cells assessed as inhibition of viral RNA replication after 24 hrs by ribonuclease protection assay Antiviral activity against HCV genotype 1b in Huh7 cells assessed as inhibition of viral RNA replication after 24 hrs by ribonuclease protection assay	[PMID: 17521911]
Vero C1008	CC₅₀	>100 μM Compound: DMA	Cytotoxicity against African green monkey Vero E6 cells Cytotoxicity against African green monkey Vero E6 cells	[PMID: 38377828]
Vero C1008	CC₅₀	>300 μM Compound: 7-DMA	Cytotoxicity against african green monkey Vero E6 cells by MTS assay Cytotoxicity against african green monkey Vero E6 cells by MTS assay	[PMID: 36455356]
Vero C1008	CC₅₀	>357 μM Compound: 7DMA	Cytotoxicity in African green monkey Vero E6 cells assessed as reduction in cell viability by MTS assay Cytotoxicity in African green monkey Vero E6 cells assessed as reduction in cell viability by MTS assay	[PMID: 30996796]
Vero C1008	EC₅₀	5.7 μM Compound: 7DMA	Antiviral activity against Zika virus MR766 infected in African green monkey Vero E6 cells assessed as reduction in virus yield Antiviral activity against Zika virus MR766 infected in African green monkey Vero E6 cells assessed as reduction in virus yield	[PMID: 30996796]

In Vivo

Oral dosing of MK-0608 results in a potent antiviral effect. In preclinical pharmacokinetic experiments with rats, dogs, and rhesus monkeys, MK-0608 demonstrates good to excellent oral bioavailability (50 to 100%) and long plasma half-lives in dogs and rhesus macaques (9 and 14 h, respectively)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

The HCV-infected chimpanzees^[1]
Dosage:

1 mg/kg
Administration:

Administered orally; once daily for 37 days
Result:

Chimpanzee X6 had a baseline viral load that varied from 1,110 to 12,900 IU/mL, and chimpanzee X4 had a baseline viral load of 3×10⁶ to 9×10⁶ IU/mL.

Chemical Information

CAS No. 443642-29-3
Appearance Solid
Molecular Weight 280.28
Formula C₁₂H₁₆N₄O₄
Color White to off-white
SMILES

OC[C@@H]1[C@@H](O)[C@](O)(C)[C@H](N2C=CC3=C2N=CN=C3N)O1
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

Nat Commun

Replicon-based genome-wide CRISPR knockout screening for the identification of host factors involved in viral replication. [Abstract]

2025 Dec 10;16(1):11028. PMID: 41372121

Solvent & Solubility

In Vitro:

DMSO : 250 mg/mL (891.97 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.5679 mL

17.8393 mL

35.6786 mL

5 mM

0.7136 mL

3.5679 mL

7.1357 mL

10 mM

0.3568 mL

1.7839 mL

3.5679 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (7.42 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (7.42 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (7.42 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Carroll SS, et al. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob Agents Chemother. 2009 Mar;53(3):926-34. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.5679 mL	17.8393 mL	35.6786 mL	89.1965 mL
	5 mM	0.7136 mL	3.5679 mL	7.1357 mL	17.8393 mL
	10 mM	0.3568 mL	1.7839 mL	3.5679 mL	8.9197 mL
	15 mM	0.2379 mL	1.1893 mL	2.3786 mL	5.9464 mL
	20 mM	0.1784 mL	0.8920 mL	1.7839 mL	4.4598 mL
	25 mM	0.1427 mL	0.7136 mL	1.4271 mL	3.5679 mL
	30 mM	0.1189 mL	0.5946 mL	1.1893 mL	2.9732 mL
	40 mM	0.0892 mL	0.4460 mL	0.8920 mL	2.2299 mL
	50 mM	0.0714 mL	0.3568 mL	0.7136 mL	1.7839 mL
	60 mM	0.0595 mL	0.2973 mL	0.5946 mL	1.4866 mL
	80 mM	0.0446 mL	0.2230 mL	0.4460 mL	1.1150 mL
	100 mM	0.0357 mL	0.1784 mL	0.3568 mL	0.8920 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

MK-0608

Anti-Infection Compound Library

Antiviral Compound Library

Nucleotide Compound Library

Anti-Hepatitis C Virus Compound Library

Heterocyclic Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

MCE Kinase Hinge Binder Fragment Library

Publications Citing Use of MedChemExpress (MCE) MK-0608

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

MK-0608

Anti-Infection Compound Library

Antiviral Compound Library

Nucleotide Compound Library

Anti-Hepatitis C Virus Compound Library

Heterocyclic Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

MCE Kinase Hinge Binder Fragment Library

Publications Citing Use of MedChemExpress (MCE) MK-0608

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

MK-0608 Related Classifications

HY-10244 Related Classifications